Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
9.89
+0.25 (2.59%)
At close: Mar 6, 2026, 4:00 PM EST
9.95
+0.06 (0.61%)
After-hours: Mar 6, 2026, 7:50 PM EST
Relay Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 15.36 | 10.01 | 25.55 | 1.38 | 3.03 | |
| Revenue Growth (YoY) | 53.44% | -60.83% | 1749.82% | -54.41% | -96.34% | |
| Cost of Revenue | 259.51 | 315.44 | 326.39 | 243.01 | 169.39 | |
| Gross Profit | -244.15 | -305.43 | -300.84 | -241.62 | -166.36 | |
| Selling, General & Admin | 58.59 | 80.24 | 78.58 | 69.33 | 59.75 | |
| Operating Expenses | 58.59 | 80.24 | 78.58 | 69.33 | 59.75 | |
| Operating Income | -302.74 | -385.67 | -379.42 | -310.95 | -226.11 | |
| Interest & Investment Income | 27.04 | 34.75 | 31.05 | 8.79 | 0.83 | |
| Other Non Operating Income (Expenses) | -0.78 | 0.01 | -0.02 | -0.02 | -0 | |
| EBT Excluding Unusual Items | -276.48 | -350.91 | -348.4 | -302.19 | -225.28 | |
| Merger & Restructuring Charges | - | - | - | - | -0.9 | |
| Gain (Loss) on Sale of Investments | - | - | - | - | -11.86 | |
| Other Unusual Items | - | 13.21 | 6.42 | 11.68 | -2.84 | |
| Pretax Income | -276.48 | -337.71 | -341.97 | -290.51 | -363.87 | |
| Net Income | -276.48 | -337.71 | -341.97 | -290.51 | -363.87 | |
| Net Income to Common | -276.48 | -337.71 | -341.97 | -290.51 | -363.87 | |
| Shares Outstanding (Basic) | 172 | 143 | 123 | 112 | 95 | |
| Shares Outstanding (Diluted) | 172 | 143 | 123 | 112 | 95 | |
| Shares Change (YoY) | 20.10% | 16.55% | 9.21% | 17.97% | 123.22% | |
| EPS (Basic) | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 | |
| EPS (Diluted) | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 | |
| Free Cash Flow | -235.87 | -251.13 | -304.44 | -238.55 | -77.88 | |
| Free Cash Flow Per Share | -1.38 | -1.76 | -2.48 | -2.13 | -0.82 | |
| Operating Margin | -1971.59% | -3854.04% | -1485.25% | -22516.44% | -7464.74% | |
| Profit Margin | -1800.58% | -3374.72% | -1338.66% | -21036.13% | -12012.94% | |
| Free Cash Flow Margin | -1536.08% | -2509.49% | -1191.74% | -17273.86% | -2571.05% | |
| EBITDA | -299.18 | -380.21 | -374.15 | -306.82 | -222.18 | |
| D&A For EBITDA | 3.56 | 5.46 | 5.27 | 4.13 | 3.93 | |
| EBIT | -302.74 | -385.67 | -379.42 | -310.95 | -226.11 | |
| Revenue as Reported | 15.36 | 10.01 | 25.55 | 1.38 | 3.03 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.